Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combining genetic proxies of drug targets and time-to-event analyses from longitudinal observational data to identify target patient populations.

BMC cardiovascular disorders - 7 May 2025

Zhang Luke, Kulkarni Prachi, Farshidfar Farshad, Tingley Whit, Hoey Tim, Wang Whedy, Priest James R, Figarska Sylwia M

Abstract excerpt

BACKGROUND: Human genetics is an important tool for identifying genes as potential drug targets, and the extensive genetic study of cardiovascular disease provides an opportunity to leverage genetics to match specific patient populations to specific drug targets to improve prioritization of patient selection for clinical studies. METHODS: We selected well described genetic variants in the region of PCSK9...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Atrial Fibrillation
Share to Cardiovascular Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glucagon-Like Peptide-1 Receptor

Share to Myocardial Ischemia

Share to Patient Selection

Share to Pharmacogenomic Testing

Share to Pharmacogenomic Variants

Share to Proprotein Convertase 9

Source

Open in PubMed Open full text

Identifiers

PMID: 40335923
DOI: 10.1186/s12872-025-04753-1
PMCID: PMC12057189

Genes

ABCC8
ACE
GLP1R
PCSK9
ADRB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combining genetic proxies of drug targets and time-to-event analyses from longitudinal observational data to identify target patient populations.PMID 40335923Read ↗

Combining Genetic Proxies of Drug Targets and Time-to-event analyses From Longitudinal Observational Data To Identify Target Patient PopulationsSemantic proximity Read ↗

Using genetics to assess the association of commonly used antihypertensive drugs with diabetes, glycaemic traits and lipids: a trans-ancestry Mendelian randomisation studySemantic proximity Read ↗

A genetic model of ivabradine recapitulates results from randomized clinical trialsSemantic proximity Read ↗

Long-Term Efficacy and Safety of GLP-1R Agonist and SGLT2 Inhibitor Therapy in the General Population: A 2x2 Factorial Mendelian Randomization StudySemantic proximity Read ↗

A genetic model of ivabradine recapitulates results from randomized clinical trials.Semantic proximity Read ↗

Genetic variants related to antihypertensive targets inform drug efficacy and side effectsSemantic proximity Read ↗

A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease.Semantic proximity Read ↗

Calcium Channel Blockers: clinical outcome associations with reported pharmacogenetics variants in 32,000 patientsSemantic proximity Read ↗

Phosphodiesterase 5 and its inhibitors with ischaemic heart disease: a Mendelian randomization analysis and a real-world study.Semantic proximity Read ↗

Combining pharmacogenetics and patient characteristic polygenic scores to improve outcome prediction for Calcium Channel Blocker treatmentSemantic proximity Read ↗

Evaluating the Impact of Putative Metformin Targets on Cancer Outcomes: A Drug-Target Mendelian Randomization Study.Semantic proximity Read ↗

Pharmacogenomic study of heart failure and candesartan response from the CHARM programmeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.